Navigation Links
Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Financial Results and Reviews Recent Developments
Date:3/11/2011

ry and metabolic diseases. Arena's most advanced drug candidate is lorcaserin, which is intended for weight management. Arena's wholly owned subsidiary, Arena Pharmaceuticals GmbH, has granted Eisai Inc. exclusive rights to market and distribute lorcaserin in the United States following FDA approval of the New Drug Application (NDA) for lorcaserin.

Arena Pharmaceuticals® and Arena® are registered service marks of the company.

Forward-Looking StatementsCertain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the advancement, therapeutic indication and use, mechanism of action, and potential of Arena's drug candidates; the potential of GPR119 and GPR119 agonists; addressing outstanding issues to the FDA's satisfaction; potential FDA approval and commercialization of lorcaserin; the Eisai collaboration and potential activities thereunder; submission of an application for European approval of lorcaserin; patent coverage; financial guidance; the reduction of Arena's workforce, including the expected size, timing, related charges and benefits; and Arena's focus, goals, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: the risk that the impact of Arena's workforce reduction may not be as expected; the risk that regulatory authorities may not find data and other information related to Arena's clinical trials and other studies meet safety or efficacy requirements or are otherwise sufficient for regulatory approval; the timing of regulatory review and approv
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Critical Pharmaceuticals Enter Sustained Release hGH Arena
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... FRANCISCO , July 2, 2015  The Green ... ), the world,s first HIPAA compliant mobile app that ... of farm-to-table fresh medical marijuana, announced today that their ... Unlike Eaze, Meadow and more than half a ... the last year, Loud Cannabis is unique in that ...
(Date:7/2/2015)... , July 2, 2015 Pharma ... stake in ZAO "Biocom" in Russia ... into the Russian pharmaceutical market which recorded RUB 765 billion ... pharmaceutical markets in the world in 2014 (IMS Health). For ... and expected to continue with this trend, projecting ...
(Date:7/2/2015)... CAMBRIDGE, Mass. , and DURHAM, N.C. ... Sciences , Inc. today announced its acquisition of assets ... Inc. (NYSE: PFE ) that had previously been ... Inc.  XRPro Sciences also acquired all of Pfizer,s rights ... re-launching the Icagen brand and will provide comprehensive services ...
Breaking Medicine Technology:New Cannabis Delivery App Gets Product to Patient in Under 7 Minutes 2Lupin Acquires Biocom in Russia 2Lupin Acquires Biocom in Russia 3Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 2Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 3Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 4
... July 22 Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced ... July 29, 2010 , before the U.S. financial markets open. , ... Anadys will hold a conference call and webcast on ... to discuss its second quarter 2010 financial results and to provide an ...
... Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that the Company will ... Wednesday, July 28, 2010 .  Neurocrine will then host a  live conference ... Thursday morning, July 29, 2010 at 8:30 a.m. Eastern Time ... , , ...
Cached Medicine Technology:Anadys Pharmaceuticals to Report Second Quarter 2010 Financial Results 2Neurocrine Biosciences Announces Conference Call and Webcast to Report Second Quarter 2010 Financial Results 2
(Date:7/4/2015)... ... ... Dating a real millionaire online can be more difficult. Millionairematchapp.com is ... remove the worries from meeting partners. Recently, the site announced they're publishing of ... readers have responded with excitement. , “There's quite a few millionaire dating apps ...
(Date:7/4/2015)... New York, NY (PRWEB) , ... July 04, 2015 , ... ... suggest that 15% of chronic pain sufferers have pain located in the neck. Another ... referred from the neck. Chiropractic literature suggests that 45% of American workers ...
(Date:7/4/2015)... ... 04, 2015 , ... Tyler Boden, Project Developer of Sullivan ... from the North American Board of Certified Energy Practitioners (NABCEP®), and is now ... and well established national certification organization for renewable energy professionals. Designation as a ...
(Date:7/3/2015)... ... July 03, 2015 , ... Brendon Burchard's new High ... of media attention. In an effort to spread the news, a comprehensive review ... days many people are feeling overwhelmed by stress and fatigue," reports Hendricks. "Many ...
(Date:7/3/2015)... SC (PRWEB) , ... July ... ... has announced the sessions and speaker lineup for its 2015 Annual ... taking place August 6-8, 2015 at the Renaissance Orlando at SeaWorld in ...
Breaking Medicine News(10 mins):Health News:MillionaireMatchapp.com Publishes the Best Millionaire Dating App and Official Dating Site Reviews 2015 2Health News:New Advancement in Treatment of Chronic Neck Pain 2Health News:New Advancement in Treatment of Chronic Neck Pain 3Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 2Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 3Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 2Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 3Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 2Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 3
... Using the Electronic Health Record to actively engage ... blood sugar and cholesterol levels, better vaccination compliance and ... study. , Geisinger Health System launched an Electronic ... in 2005. A study published in Aprils Journal of ...
... and Cons of Approach to Eliminating HAIs, ORLANDO, ... emerging drive to eliminate infections acquired in hospitals -,is ... that the approach is overly simplistic and potentially dangerous ... Healthcare experts will,discuss the hot-button issue at the Annual ...
... critical lack of,family and paraprofessional caregivers for older ... the Community College Caregiver Training,Initiative for a second ... Caregiving Project for Older,Americans, a project housed within ... for Proposals (RFP) and will award up to,twelve ...
... (Nasdaq: NXXI ), a developer and marketer of ... cardiovascular,health, enhance memory and address chronic joint pain today ... Company,s Board of Directors,effective April 7, 2008., Mr. ... Iceland,Health, Inc. a company acquired by Nutrition 21 in ...
... blood or bone marrow is caused by mutations ... healthy blood. To devise effective therapies it is crucial ... type gives rise to leukaemic cells. Researchers from the ... Bioinformatics Institute, UK, and the Universities of Harvard, USA, ...
... Celebrates 40 Years of Specialized ... the U.S. and Abroad April 13-19, MT LAUREL, N.J., April ... the United States, the world and Enterostomal,Therapy (ET) Nursing. The end ... beginning of the end of the,Vietnam War influenced world events. And ...
Cached Medicine News:Health News:Geisinger improves care for thousands of diabetics through use of the Electronic Health Record 2Health News:The 'Zero' Mentality: Is It Good for Infection Control? 2Health News:ILC-USA and MetLife Foundation Launch Second Year of Community College Caregiver Training Grants 2Health News:Nutrition 21 Elects Mark H. Stenberg to Board of Directors 2Health News:An unexpected way to cause leukemia 2Health News:WOCN: Around the World in 40 Years 2Health News:WOCN: Around the World in 40 Years 3Health News:WOCN: Around the World in 40 Years 4
Antibiotics (Gentamicin) loaded, low viscosity bone cement for syringe use with an average setting time of approx. 7-9 Min., 41.6g of powder and 16.4g of liquid....
Antibiotics (Gentamicin) loaded, high viscosity bone cement for digital use with an average setting time of approx. 6-8 Min., 41.6g of powder and 14.4g of liquid....
... provide superior image quality and light ... camera head with a C-mount thread. ... light at the operative site while ... clarity and reliability.,The Videoscopes have completely ...
... Solitaire represents the latest in green laser technology, ... in both the operating room and clinic. Designed ... the premium 532nm photocoagulator. , ,The Solitaire is ... the flexibility to deliver up to 2.0 W ...
Medicine Products: